| 1 |
33954816 | Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. | 2022 Mar |
1 |
| 2 |
34976720 | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. | 2022 |
1 |
| 3 |
35368106 | Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis. | 2022 Apr 3 |
1 |
| 4 |
35577753 | SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. | 2022 Jul |
1 |
| 5 |
34255353 | Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. | 2021 Oct 15 |
1 |
| 6 |
32172299 | Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. | 2020 Mar 14 |
1 |
| 7 |
33425404 | Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review. | 2020 |
1 |
| 8 |
30608891 | Lenalidomide for the treatment of mantle cell lymphoma. | 2019 Apr |
1 |
| 9 |
31048321 | Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. | 2019 Jul |
2 |
| 10 |
31542870 | Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. | 2019 Oct |
1 |
| 11 |
29561706 | Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. | 2018 May |
2 |
| 12 |
28782884 | Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. | 2017 Sep |
1 |
| 13 |
29250930 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia. | 2017 Dec |
1 |
| 14 |
27069256 | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. | 2016 Jun 23 |
1 |
| 15 |
27913471 | Sequencing of chronic lymphocytic leukemia therapies. | 2016 Dec 2 |
1 |